Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Coxiella burnetii in non-Hodgkin lymphoma tissue samples: Innocent until proven otherwise?

Autor: van Roeden, Sonja E., Hermans, Mirjam H.A., Nooijen, Peet T.G.A., Herbers, Alexandra, Bleeker-Rovers, Chantal P., Hoepelman, Andy I.M., Oosterheert, Jan Jelrik, Wever, Peter C.

Publikováno v: In Immunobiology March 2019 224(2):254-261

Rituximab‐ PECC induction followed by 90 Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT : results from a phase II HOVON study

Autor: Lugtenburg, Pieternella J, Zijlstra, Josee M, Doorduijn, Jeanette K, Böhmer, Lara H, Hoogendoorn, Mels, Berenschot, Henriette W, Beeker, Aart, van der Burg-de Graauw, Nicole C, Schouten, Harry C, Bilgin, Yavuz M, Kersten, Marie-Jose, Koene, Harry R, Herbers, Alexandra H E, de Jong, Daphne, Hijmering, Nathalie, Lam, King H, Chiţu, Dana, Brouwer, Rolf E, van Imhoff, Gustaaf W

Publikováno v: British Journal of Haematology, 187(3), 347-355. Wiley
British Journal of Haematology, 187(3), 347-355. Wiley-Blackwell Publishing Ltd

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etopo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3a5a9275e83857f2214d979536b839da
https://cris.maastrichtuniversity.nl/en/publications/adc39e10-7463-48ff-b6dd-4f5df887f6da

Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Autor: Lugtenburg, Pieternella J., Zijlstra, Josee M., Doorduijn, Jeanette K., Böhmer, Lara H., Hoogendoorn, Mels, Berenschot, Henriette W., Beeker, Aart, van der Burg-de Graauw, Nicole C., Schouten, Harry C., Bilgin, Yavuz M., Kersten, Marie-Jose, Koene, Harry R., Herbers, Alexandra H. E., de Jong, Daphne, Hijmering, Nathalie, Lam, King H., Chiţu, Dana, Brouwer, Rolf E., van Imhoff, Gustaaf W.

Publikováno v: Lugtenburg, P J, Zijlstra, J M, Doorduijn, J K, Böhmer, L H, Hoogendoorn, M, Berenschot, H W, Beeker, A, van der Burg-de Graauw, N C, Schouten, H C, Bilgin, Y M, Kersten, M-J, Koene, H R, Herbers, A H E, de Jong, D, Hijmering, N, Lam, K H, Chiţu, D, Brouwer, R E, van Imhoff, G W & the Dutch HOVON group 2019, ' Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study ', British Journal of Haematology, vol. 187, no. 3, pp. 347-355 . https://doi.org/10.1111/bjh.16087
British Journal of Haematology, 187(3), 347-355. Wiley-Blackwell
British journal of haematology, 187(3), 347-355. Wiley-Blackwell

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etopo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::67d0628a8b671ff7539f87f2ea5264be
https://research.vumc.nl/en/publications/83f5a36e-71a9-4023-a0a7-7b829de79611

Acute Myelogenous Leukemia and Febrile Neutropenia

Autor: Herbers, Alexandra, de Pauw, Ben E.

Publikováno v: Managing Infections in Patients With Hematological Malignancies

Aggressive chemotherapy has a deleterious effect on all components of the defense system of the human body. The resulting neutropenia as well as injury to the pulmonary and gastrointestinal mucosa allow pathogenic micro-organisms easy access to the b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmc_________::fbd7a46893fb1da92b7f3f79ed215bf8
http://europepmc.org/articles/PMC7121946